Discussion
neutropenia, fatigue, leukopenia, stomatitis, cardiotoxicity, alopecia
ALOPECIA, NEUTROPENIA, LEUKOPENIA, STOMATITIS
This study first evaluated the efficacy and safety of DuomeisuAn unmet need exists for patients with heavily pretreated HER2-negative MBC. After anthracycline and taxane failure, there is no optimal chemotherapy regimen established for such patients [More recently, eribulin, a novel non-taxane microtubule inhibitor, was approved as monotherapy for the treatment of MBC previously treated with anthracyclines and taxanes based on results of EMBRACE [Currently, novel antibody–drug conjugates (ADCs) are rapidly evolving therapies for heavily pretreated HER2-negative MBC, including trastuzumab deruxtecan (T-DXd) [The overall safety profile was good in this study. No grade 4/5 AEs were observed. The most frequently reported AEs were leukopenia, fatigue, and neutropenia. The most common grade 3 AEs were neutropenia (7.3%) and fatigue (4.9%). All grades of PPE were 24.4% with 2.4% grade 3, and all grades of stomatitis 9.5% with no grade 3. Only three patients (7.3%) experienced grade 1 alopecia. Regarding cardiotoxicity, most patients (97.6%) had no significant decrease in LVEF during treatment, and only one patient experienced a decrease in LVEF from 70% at baseline to 62% after five cycles of PLD. These findings were consistent with those in the previous studies of PLD 10 mg/mThis study had several limitations. First, this study had a single-center, open-label design with no control arm. Second, the implementation of the study took longer than originally planned. The slow enrollment of patients was aggravated by the COVID-19 pandemic. Third, this was an exploratory trial with small sample sizes.